Companies /Healthcare

Summit Therapeutics Inc

NASDAQ: SMMT Biotechnology
$11.23
▲ $0.56 (+5.25%) today
Markets open · 10:27am ET

24/7 Wall St. View

SMMT at a Glance

Valuation
Market cap
$8.6B
Profitability
EPS (TTM)
$-1.06
Price
52-week range
$11 – $29
Street target
$29.48

Headquartered in Miami, FL Fiscal year ends December NASDAQ: SMMT smmttx.com

About Summit Therapeutics

Summit Therapeutics Inc. is a clinical-stage biopharmaceutical oncology company with no product revenue. Its business centers on ivonescimab (SMT112), an investigational bispecific antibody that combines PD-1 immune checkpoint blockade with VEGF anti-angiogenesis in a single tetravalent molecule. Summit in-licensed ivonescimab from Akeso Inc. in January 2023. It holds exclusive development and commercialization rights in North America, South America, Europe, the Middle East, Africa and Japan; Akeso retains rights elsewhere, including China, where the drug has been approved since May 2024. Summit sponsors five global Phase III studies: HARMONi, HARMONi-3 and HARMONi-7 in NSCLC, HARMONi-GI3 in colorectal cancer, and HARMONi-GU1 in bladder cancer. It also runs a Phase II study in clear cell renal cell carcinoma and supports cooperative-group Phase III studies in head and neck cancer (ILLUMINE) and biliary tract cancer (EA2251). A BLA for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC has a PDUFA date of November 14, 2026. Summit pursues combination collaborations with AstraZeneca, Daiichi Sankyo, GSK, Revolution Medicines and Arcus Biosciences, and supports more than 65 investigator-sponsored trials. In October 2026, AstraZeneca completed a $2.0 billion strategic equity investment in the company. Summit funds operations through equity, including an at-the-market offering program. Updated

SMMT Coverage

8:45am ET
Investing

Elon Musk Leads Insider Buying Wave

The highlight of recent insider buying is an enormous purchase of Tesla shares by CEO Elon Musk. But it wasn't the only notable buy in the past week or so.

Trey Thoelcke

Frequently Asked Questions

What does Summit Therapeutics do?

Summit Therapeutics Inc. is a clinical-stage biopharmaceutical oncology company with no product revenue. Its business centers on ivonescimab (SMT112), an investigational bispecific antibody that combines PD-1 immune checkpoint blockade with VEGF anti-angiogenesis in a single tetravalent molecule.

What is the SMMT stock price target?

The Wall Street consensus 12-month price target for SMMT is $29.48. SMMT price prediction →